Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Key Players companies in Ribociclib
by Most News Heat in the Japan in 2022

The Ribociclib top 20 is Discovery PatSnap’ annual ranking of the top 20 Most News Heat Ribociclib Key Players in the Japan. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Medicine,Health care,Clinical trial,
...[+2]
news: 3
2
Clinical trial,Cardiovascular agent,Drug,
...[+2]
news: 2
3
news: 2
4
news: 1
5
news: 1
6
news: 1
7
Health care,Over-the-counter,Clinical trial,
...[+2]
news: 1
8
news: 1
9
Project appraisal,Core system,Business process outsourcing,
...[+2]
news: 1
10
news: 1
11
Kintetsu Department Store Co., Ltd.
Food products,Fast-moving consumer goods,Warehouse
news: 1
12
Hematology,Medicine,Pharmacy and Therapeutics,
...[+2]
news: 1
13
news: 1
14
news: 1
15
news: 1
16
Fellow System
news: 1
17
news: 1
18
Ventus, Inc.
news: 1
19
The company Japan
news: 1
20
Frontier Institute Co. Ltd.
news: 1
Page generation time: Jul 07 2025